/** Title: Lord’s Mark Industries: Scaling MedTech Ambitions While Renewables Anchor Near-Term Visibility */

Lord’s Mark Industries: Scaling MedTech Ambitions While Renewables Anchor Near-Term Visibility

Lord’s Mark Industries Limited, a BSE-listed company, used its September 2026 investor communication and conference call to position itself as a two-vertical platform: healthcare (in vitro diagnostics, MedTech devices, dialysis, and genomics) and renewable energy and LED lighting (largely government and public sector programs). The company’s central pitch is that healthcare can become a higher-margin growth engine, while renewables and lighting provide a contracted base of orders.

Management also provided explicit near-term financial guidance on the call. For FY27, it guided to consolidated revenue of around INR 1,550 crore, with an EBITDA margin of around 20.8 percent and a PAT margin of around 12.8 percent. Management added that it expects operating cash flow to turn positive in FY27, and if not, then by the second quarter of the next financial year.

Two verticals, one strategy: build healthcare scale while executing a government-heavy order book

The investor presentation frames Lord’s Mark around two primary divisions: IVD and MedTech, and renewable energy (solar) and LED lighting. The company states it operates across India with a presence in 15 plus states, a network of 700 plus distributors, and 200 plus enterprise clients. It also described a push toward exports, citing a maiden order in the United States and growing intent across SAARC, GCC, and Europe.

Renewables and LED are presented as a government-anchored business with a stated secured order book of around INR 2,000 crore and an overall pipeline of over INR 3,000 crore. The presentation links this to programs such as PM Surya Ghar and state agencies like UPNEDA, BREDA, EESL, and APDCL.

Healthcare, meanwhile, is positioned as an “integrated platform” spanning diagnostic reagents and rapid kits, analyzers, new devices, and genomics. A key element of the thesis is in-house manufacturing and regulatory positioning. The company states it holds a single-roof Central Drugs Standard Control Organization licence covering rapid tests, reagents, and analyzers, alongside multiple approvals across product categories.

Financial snapshot and explicit management guidance

The company’s disclosed and guided numbers in the materials span different contexts (forecast tables in the presentation and guidance on the call). The most directly attributable management guidance from the call is included below.

Healthcare build-out: diagnostics scale plus Renalyx-led dialysis expansion

A large part of the company’s healthcare narrative rests on diagnostics manufacturing and a product portfolio that management argues can shift from one-time sales to recurring consumables. In the call, management explained the “razor and blade” logic: analyzers placed in the field, with recurring reagent sales tied to those placements.

The second major step is dialysis. The investor presentation states Lord’s Mark acquired 85 percent of Renalyx Health Systems, which it describes as an indigenous, cloud-connected dialysis machine platform with European CE standards and multi-year clinical trials. The company also claims its dialysis machine reduces water usage materially compared to conventional machines.

On the call, management discussed dialysis adoption and capacity in more operational terms. It stated a confirmed order book of over 500 dialysis machines and said manufacturing capacity is about 60 machines per month currently, with a potential scale-up to 150 machines per month by end of next year. It also described a move toward dialysis-as-a-service, with an operating target of 50 dialysis centers by March 2027, and 15 centers already operational.

Management also shared a broad cost framework for centers, stating that a 10-machine dialysis center could cost around INR 1.5 to 1.8 crore to establish. It added that in many cases partners fund the infrastructure while Lord’s Mark focuses on installation and operations.

From an investor lens, the dialysis model is intended to create recurring revenue through consumables and pay-per-treatment economics. The investor presentation includes a Renalyx revenue model that explicitly splits revenue into outright sale, leasing, pay-per-treatment, annual maintenance contracts, and consumables.

Renewables and LED: large pipeline, but working-capital dynamics remain central

The renewable energy and LED vertical is described as a government-heavy execution business. The presentation cites multi-year contracts and relationships with state agencies and PSUs. It also claims specialized capability such as lighting design for naval applications, alongside execution across programs in multiple states.

However, the same characteristics that drive size and visibility can also pressure cash conversion. In Q and A, a participant highlighted receivables of around INR 450 crore in the June quarter and asked when operating cash flows might turn positive. Management responded that the disclosed audited balance sheet on the exchange covered only six months due to the reverse merger timeline, and said receivables should be viewed against a consolidated full-year revenue base.

Still, the presentation itself includes government payment cycles as an explicit risk, noting that state and PSU receivables can be slower than private sales, and that mitigation is expected through diversification and growth in exports and private mix.

Corporate actions and capital plan: dilution, fundraise, and demerger roadmap

Beyond operating plans, Lord’s Mark highlighted several capital market and structural milestones. The presentation sets out a plan for an FY27 fundraise, with an FPO or preferential allotment of INR 500 crore in March 2027. It specifies the proposed split: INR 325 crore for a MedTech manufacturing facility and INR 175 crore for working capital and operations.

The call also discussed minimum public shareholding compliance. The moderator noted the company is yet to meet the minimum public shareholding requirement, and management said it intends to dilute promoter holdings to 75 percent through a mix of offer for sale and other issuance, and that Nuvama has been appointed as merchant banker and advisor.

Separately, the investor presentation outlines a planned FY28 demerger and a broader corporate structure reimagining, with the stated objective of maximizing valuation by separating verticals.

Key investor takeaways from the documents

First, Lord’s Mark has provided explicit FY27 revenue and margin guidance, which creates a clear benchmark for the market to track. Second, renewables and LED are positioned as an order-book driven business with stated contracted visibility, but the same model brings working-capital sensitivity, as reflected in investor questions on receivables.

Third, healthcare expansion is being framed around both regulatory positioning in IVD and a higher-margin dialysis business through Renalyx. The dialysis roadmap is specific in terms of center rollout targets and capacity discussions. Finally, the next 12 to 24 months also include capital market dependencies: minimum public shareholding compliance, a proposed fundraise, and a structural demerger roadmap.

The core questions investors may continue to watch, based strictly on management’s own discussion, are: whether cash flows turn positive in the stated timeframe, whether receivables reduce in line with sales growth, and whether product approvals and commercialization timelines remain on track for the healthcare pipeline.